QNCX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
QNCX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-16), Quince Therapeutics's share price is $2.03. Quince Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was $1.04. Hence, Quince Therapeutics's PB Ratio of today is 1.96.
The historical rank and industry rank for Quince Therapeutics's PB Ratio or its related term are showing as below:
During the past 7 years, Quince Therapeutics's highest PB Ratio was 24.76. The lowest was 0.00. And the median was 0.00.
During the past 12 months, Quince Therapeutics's average Book Value Per Share Growth Rate was -54.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -30.20% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Quince Therapeutics was -13.50% per year. The lowest was -30.20% per year. And the median was -21.85% per year.
The historical data trend for Quince Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quince Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
PB Ratio | Get a 7-Day Free Trial | 13.06 | 4.76 | 3.20 | 0.23 | 0.53 |
Quince Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PB Ratio | Get a 7-Day Free Trial | 0.49 | 0.53 | 0.62 | 0.69 | 0.75 |
For the Biotechnology subindustry, Quince Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Quince Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Quince Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Quince Therapeutics's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Sep. 2024) |
= | 2.03 | / | 1.038 | |
= | 1.96 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Quince Therapeutics (NAS:QNCX) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Quince Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Dirk Thye | director, officer: Chief Executive Officer | 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Brendan Hannah | officer: Chief Business Officer | 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Charles S. Ryan | officer: President | C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790 |
David Lamond | director | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Guenter Janhofer | officer: Chief Scientific Officer | 601 GATEWAY BOULEVARD, SUITE 1250, SOUTH SAN FRANCISCO CA 94080 |
Luca Benatti | director | C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011 |
Margaret Mcloughlin | director | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Ted Monohon | officer: Chief Accounting Officer | C/O FANTEX, INC., 330 TOWNSEND ST., SUITE 234, SAN FRANCISCO CA 94107 |
June Bray | director | C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511 |
Caryn Gordon Mcdowell | officer: Chief Legal & Adm. Officer | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Philip S Low | director | 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906 |
Karen L. Smith | officer: Chief Medical Officer | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Marwan Sabbagh | director | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Stephen S. Dominy | director, officer: Chief Scientific Officer | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94105 |
Christopher P. Lowe | officer: Chief Financial Officer | 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258 |
From GuruFocus
By Business Wire • 09-03-2024
By Business Wire • 06-03-2024
By Business Wire • 11-12-2024
By Business Wire • 01-04-2024
By Business Wire • 02-12-2024
By GuruFocus Research • 02-08-2024
By Business Wire • 11-11-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.